Search
Akari Therapeutics PLC
AKTXAdd to Watchlist
10.410USD
+0.160+1.56%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
11.92MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
4
analysts
Buy
Current Rating
35.667
Target Price
+247.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
Akari Therapeutics PLC
AKTX
4
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
AbbVie Inc
ABBV
33
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Akari Therapeutics PLC's price target?
Analysts forecast that Akari Therapeutics PLC's price target is USD 5.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 1.60.
How have Akari Therapeutics PLCAKTX's recent earnings per share performed?
The market expectation was USD -9.60, while Akari Therapeutics PLCAKTX's earnings per share (EPS) for the previous quarter was USD -0.12. EPS for the next quarter is expected at USD -1.40.
What is the analyst rating for Akari Therapeutics PLC?
Based on the ratings of Akari Therapeutics PLC's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.